Physician profile
Timothy Jones
NPI 1467453498
$1,356.28
in general payments reported to CMS, 2019-2025
24 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $153 · 2021: $18.24 · 2022: $33.35 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $205.17 | 2019-2025 | Airsupra |
| Allergan, INC. | $162.05 | 2019 | |
| Pfizer INC. | $115.30 | 2019-2025 | |
| Janssen Biotech, INC. | $113.52 | 2019 | |
| Merck Sharp & Dohme LLC | $75.87 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.55 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.89 | 2019-2020 | |
| Gilead Sciences, INC. | $64.29 | 2019-2020 | |
| Amgen INC. | $63.56 | 2019-2025 | Repatha, Otezla |
| Emd Serono, INC. | $58.75 | 2019-2020 | |
| Lilly USA, LLC | $48.69 | 2025 | Zepbound, Mounjaro, Kisunla |
| Exact Sciences Corporation | $46.31 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $35.38 | 2019 | |
| Novo Nordisk INC | $33.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.51 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $32.33 | 2019 | |
| Vyera Pharmaceuticals, LLC | $19.26 | 2020 | |
| Abbvie INC. | $18.24 | 2021 | |
| Viiv Healthcare Company | $17.72 | 2022 | |
| Harmony Biosciences LLC | $15.97 | 2025 | |
| Dexcom, INC. | $15.83 | 2025 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $15.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.